Acceptability of HIV Oral PrEP Among MSM and TGW
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02855606|
Recruitment Status : Unknown
Verified January 2017 by Suwat Chariyalertsak, Chiang Mai University.
Recruitment status was: Recruiting
First Posted : August 4, 2016
Last Update Posted : February 2, 2017
|Condition or disease|
|Patient Acceptance of Health Care|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Acceptability of HIV Oral Pre-Exposure Prophylaxis (PrEP) Among Men Have Sex With Men (MSM) and Transgender Women (TGW)|
|Actual Study Start Date :||December 2015|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||June 2018|
- Acceptability and factors affecting the decision to take oral PrEP [ Time Frame: 1 year ]After receiving information about PrEP, the participants will have a chance to decide whether they want to take PrEP or not. The set of questions asking about reason(s) for taking (or not taking) PrEP are used to evaluated the acceptability. The questions will evaluate multiple aspects such as knowledge about PrEP (efficacy and medications side effect), personal belief about PrEP, sexual practice, social stigmata, and concern for HIV resistance. The participants will answer these questions via Computer-Assisted Self Interviewing (CASI).
- Adherence to PrEP by self-report [ Time Frame: 1 year ]Among the participants who decide to take PrEP, the adherence will be evaluate by self-report (directly to medical staff and via Computer-Assisted Self Interviewing).
- Adherence to PrEP by pill count [ Time Frame: 1 year ]Among the participants who decide to take PrEP, the adherence will be evaluate by pill count.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02855606
|Contact: Suwat Chariyalertsak, MD. DrPH.||66-53-936148 ext email@example.com|
|Chiang Mai, Thailand, 50200|
|Contact: Radhcanok Songsupa 6653211 363|
|Contact: Pongpun Saokhieo|
|Sub-Investigator: Quanhathai Kaewpoowat, MD|
|Principal Investigator:||Suwat Chariyalertsak, MD. DrPH.||Research Institute for Health Sciences (RIHES)|